Julia Cleary

Executive Business Partner | Research & Corporate Strategy at Kymera Therapeutics
  • Claim this Profile
Contact Information
us****@****om
(386) 825-5501
Location
Boston, Massachusetts, United States, US

Topline Score

Topline score feature will be out soon.

Bio

Generated by
Topline AI

You need to have a working account to view this content.
You need to have a working account to view this content.

Experience

    • United States
    • Biotechnology Research
    • 100 - 200 Employee
    • Executive Business Partner | Research & Corporate Strategy
      • Nov 2021 - Present

      Kymera Therapeutics is a clinical stage biopharmaceutical company pioneering a transformative new modality, “targeted protein degradation” (TPD), with the ability to pursue targets long considered undruggable and to treat disease in entirely new ways. Its mission is to discover, develop and commercialize novel and transformative therapies to improve the lives of patients with serious diseases. Our team has developed a proprietary drug discovery engine, Pegasus, to enable the design of highly selective, small molecule protein degraders with potent activity against a broad range of disease indications. We are committed to selecting targets with the broadest possible impact across multiple disease indications with high unmet medical need to realize the full potential of TPD. Show less

    • United States
    • Biotechnology Research
    • 1 - 100 Employee
    • Executive Assistant | Research & Development
      • Apr 2017 - Nov 2021

      Translate Bio is the amalgamation of two passionate teams of scientists with one shared mission: to transform RNA science into revolutionary medicines. Our story begins in a lab in 2008 in Lexington, Mass, where a skilled group of researchers was developing a technology to test whether messenger RNA could be used to treat a wide range of diseases. Fast forward to 2011, when a small Cambridge, Mass, biotech company called RaNA Therapeutics was founded to discover and develop methods of treating genetic disease by modulating the actions of long non-coding RNA. In 2017, these two groups joined together to form Translate Bio. Representing a decade of RNA expertise and know-how, we are now a leading RNA therapeutics company using the body’s own machinery to produce proteins and transformative medicines to combat disease from within. Show less

    • United States
    • Biotechnology
    • 1 - 100 Employee
    • Executive Assistant | Research & Development
      • Apr 2017 - Jun 2017

      RaNA Therapeutics is now Translate Bio. Translate Bio is a leading biotechnology company focused on pioneering the translation of RNA science into therapeutics promoting healthy gene expression in people living with debilitating genetic diseases. The company’s RNA platforms for powering endogenous therapeutic protein production is applicable to a broad range of diseases caused by insufficient protein production, including rare diseases of the liver, lung and central nervous system (CNS). RaNA Therapeutics is now Translate Bio. Translate Bio is a leading biotechnology company focused on pioneering the translation of RNA science into therapeutics promoting healthy gene expression in people living with debilitating genetic diseases. The company’s RNA platforms for powering endogenous therapeutic protein production is applicable to a broad range of diseases caused by insufficient protein production, including rare diseases of the liver, lung and central nervous system (CNS).

    • United States
    • Biotechnology Research
    • 1 - 100 Employee
    • Executive Assistant and Office Manager
      • Apr 2016 - Apr 2017

      Alzheon, Inc. is committed to developing innovative medicines for patients suffering from Alzheimer’s disease and other neurological and psychiatric disorders. Our lead clinical product candidate, ALZ-801, is an oral inhibitor of amyloid aggregation and neurotoxicity - hallmarks of Alzheimer’s disease. ALZ-801 is an optimized, novel prodrug that builds on the safety and efficacy profile of the active compound in clinical trials of more than 2,000 patients. Our mission is to apply our discovery platform and development experience to develop new classes of therapeutics that make a difference in patients’ lives by directly addressing the underlying pathology of devastating neurodegenerative disorders. Show less

    • Ireland
    • Biotechnology Research
    • 1 - 100 Employee
    • Executive Assistant | Medical Affairs
      • Apr 2014 - Apr 2016

      Aegerion Pharmaceuticals is a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare diseases. Aegerion Pharmaceuticals is a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare diseases.

    • United States
    • Hospitals and Health Care
    • 700 & Above Employee
    • Executive Assistant | Clinical Services
      • May 2004 - Apr 2014

      Boston's Brigham and Women's Hospital (BWH) is an international leader in virtually every area of medicine and has been the site of pioneering breakthroughs that have improved lives around the world. A major teaching hospital of Harvard Medical School, BWH has a legacy of excellence that continues to grow year after year. Brigham and Women’s Health Care – the parent corporation for Brigham and Women’s Hospital, Brigham and Women’s Faulkner Hospital and the Brigham and Women’s Physician Organization – includes 150 outpatient practices with over 1,200 physicians. We serve patients from New England, throughout the United States, and from 120 countries around the world. Show less

    • Canada
    • Hospitality
    • 700 & Above Employee
    • Executive Assistant | Sales & Marketing
      • Jan 1995 - May 2004

      Four Seasons Hotels and Resorts, is a Canadian international luxury, five-star hospitality company. Travel + Leisure magazine and Zagat Survey rank the hotel chain's 98 properties among the top luxury hotels worldwide. Readers of Conde Nast Traveler magazine have voted the company's Camp Golden Triangle in Chiang Mai, Thailand as among the top ten hotels in the world for three consecutive years. The company has been named one of the "100 Best Companies to Work For" by Fortune every year since the survey's inception in 1998, ranking #47 in 2015, and is lauded for having one of the lowest employee turnover rates in the hospitality industry. Show less

Community

You need to have a working account to view this content. Click here to join now